Efficacy and safety of Xileisan combined with mesalazine for ulcerative colitis: A meta-analysis and trial sequential analysis

Table 3 The results of subgroup analysis for Xileisan dosage, mesalazine dosage, and treatment duration

Subject	Subgroup	I2	RR (95%CI)	P value
XLS dosage	1.0 g/d	0	1.23 (1.15-1.30)	< 0.00001
	2.0 g/d	0	1.16 (1.03-1.31)	0.01
Mesalazine dosage	1.0-2.0 g/d	0	1.15 (1.01-1.32)	0.04
	3.0 g/d	3	1.20 (1.11-1.30)	< 0.00001
	4.0 g/d	0	1.26 (1.15-1.37)	< 0.00001
Treatment duration	2 weeks	0	1.17 (1.00-1.38)	0.05
	3 weeks	0	1.26 (1.12-1.42)	0.0002
	4 weeks	0	1.23 (1.14-1.34)	< 0.00001
	8 weeks	33	1.16 (1.05-1.29)	0.003

XLS: Xileisan; RR: Risk ratio.